anti-ROR1 mAbs (National Cancer Institute)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-ROR1 mAbs (National Cancer Institute)
Drug Alias Name2D11 mAb1A7 mAb1A1 mAb2A2 mAb
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists
TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institutes Of HealthNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A